Bulletin
Investor Alert

Topics

Earnings

Video

Catalysts for Bitcoin to Hit $20k

  • Catalysts for Bitcoin to Hit $20k Catalysts for Bitcoin to Hit $20k 10:01
12:49 p.m. May 13, 2021 - By Claudia Assis
GoodRx stock heads lower after mixed Q1 resultsShares of GoodRX Holdings Inc. fell more than 5% in the extended session Thursday after the health-care company reported first-quarter sales slightly below Wall Street expectations and met the forecast for adjusted profit. GoodRx said it earned $1.7 million, breaking even on a per-share basis, in the quarter, compared with $27.3 million, or 8 cents a share, in the year-ago quarter. Adjusted for one-time items, the company earned 7 cents a share. Sales rose 20% to $160.4 million, the company said. Analysts polled by FactSet expected GoodRX to earn an adjusted 7 cents a share on sales of $160.6 million. Monthly active consumers rose 17% to 5.7 million people, it said. GoodRX guided for second-quarter revenue between $172 million and $176 million, and full-year 2021 revenue between $740 million and $760 million. The stock ended the regular trading day down 4%.
4:43 a.m. May 13, 2021 - By Jaimy Lee
One Medical's parent company says COVID-19 testing volume 'meaningfully' declined in April1Life Healthcare Inc. , which operates the One Medical direct primary care business, on Wednesday told investors that it started seeing a "meaningful drop" in COVID-19 testing in April as a greater number of Americans were vaccinated against the virus and the number of coronavirus cases in the U.S. continued to decline. 1Life CFO Bjorn Thaler cited a "faster-than-anticipated education in COVID-19 testing volumes," according to a FactSet transcript of the company's call. "As we look at the rest of the year, certainly we don't expect those numbers to come back," Thaler added. 1Life's stock is down 12.2% for the year, while the broader S&P 500 is up 8.1%.
3:50 a.m. May 10, 2021 - By Jack Denton
BioNTech shares soar 8% as COVID-19 vaccines drive revenue surgeShares in BioNTech surged 8% in premarket trading on Monday, after the German biotechnology group reported first-quarter earnings. Jointly with Pfizer , BioNTech co-developed the first COVID-19 vaccine to receive the green light from regulators following large-scale clinical trials. The group reported revenue of €2.05 billion ($2.49 billion) in the first three months of the year, outpacing expectations for €1.7 billion, according to FactSet consensus. Revenue in the same period in 2020 was €27.7 million. Net profit surged €1.13 billion in the first quarter of 2021, up from €53.4 million in 2020. BioNTech said that it had supplied more than 450 million doses of its COVID-19 vaccine to 91 countries or territories as of May 6, with signed agreements for more than 1.8 billion doses in 2021. The estimated revenue from COVID-19 vaccine deliveries, based on the currently signed contracts, is €12.4 billion. The group said there was no evidence that its COVID-19 vaccine needed to be adapted to deal with variants of the virus that have been identified.
2:12 a.m. May 7, 2021 - By Tomi Kilgore
Cigna stock gains, as profit and revenue rise above expectationsShares of Cigna Corp. gained 0.5% in premarket trading Friday, after the health services company reported first-quarter profit and revenue that rose above expectations, as total customer relationships grew 14% and pharmacy customers increased 28%. Net income was $1.16 billion, or $3.30 a share, compared with $1.18 billion, or $3.15 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $4.73 from $4.69, beating the FactSet consensus of $4.37. Revenue grew 6.5% to $40.97 billion, above the FactSet consensus of $40.21 billion. Customer relationships increased to 189.9 million from 167.0 million, as pharmacy customers rose to 101.0 million from 78.8 million. Cigna's stock has rallied 23.4% year to date through Thursday, while the S&P 500 has advanced 11.9%.
3:21 a.m. May 6, 2021 - By Ciara Linnane
Cardinal Health shares slide 8.8% premarket after earnings fall short of esimatesCardinal Health Inc. shares slid 8.8% in premarket trade Thursday, after the drug distributor posted weaker-than-expected earnings for its fiscal third quarter and lowered the top end of its guidance. The company said net income fell to $119 million, or 40 cents a share, in the quarter to March 31, down from $350 million, or $1.19 a share, in the year-earlier period. Excluding special items, adjusted EPS came to $1.53, just below the $1.55 FactSet consensus. Revenue rose to $39.3 billion from $39.2 billion, also below the FactSet consensus of $40.1 billion. The company narrowed its fiscal 2021 adj. EPS guidance range to $5.90 to $6.05 from previous guidance of $5.85 to $6.10. Shares have gained 13.6% in the year to date, while the S&P 500 has gained 11%.
2:15 a.m. May 6, 2021 - By Tomi Kilgore
Becton Dickinson beats profit expectations, plans to spin off Diabetes Care businessBecton Dickinson & Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by $480 million in COVID-19 testing sales, and announced plans to separate its Diabetes Care business into an independent publicly traded company. The medical technology company's stock was still inactive in premarket trading. Net income for the quarter to March 31 rose to $277 million, or 95 cents a share, from $145 million, or 53 cents a share, in the year-ago period. Excluding nonrecurring items, such as purchase accounting adjustments and European regulatory initiative related costs, adjusted earnings per share came to $3.19, above the FactSet consensus of $3.04. Revenue grew 15.4% to $4.91 billion, topping the FactSet consensus of $4.89 billion, as medical revenue rose 1.7% and life sciences revenue increased 10.4% while interventional revenue fell 3.9%. For 2021, the company expects adjusted EPS growth of 24% to 25%, while the FactSet consensus of $12.86 implies 26.1% growth. Separately, the company said it expects the spinoff to occur through a distribution of stock in the new company to its shareholders, with the deal expected to be completed in the first half of 2022. The stock has lost 1.9% over the past three months, while the S&P 500 has gained 7.2%.
1:21 a.m. May 6, 2021 - By Steve Goldstein
Vaccine makers lower after U.S. says it supports IP waiversVaccine makers Pfizer , BioNTech and Moderna each traded lower by 3% to 5% in premarket trade on Thursday, following the announcement from U.S. Trade Representative Katherine Tai that the U.S. supports the waiver of intellectual-property protections on COVID-19 vaccines. Another maker of COVID-19 vaccines, AstraZeneca , was flat in London trade. Moderna also is scheduled to report earnings on Thursday.
2:42 a.m. May 5, 2021 - By Tomi Kilgore
AmerisourceBergen stock falls after profit beats forecasts but revenue was a bit lightShares of AmerisourceBergen Corp. fell 0.7% in premarket trading Wednesday, after the pharmaceuticals and health care products company reported a first-quarter profit that beat expectations but revenue that came up a bit light. Net income fell to $435.3 million, or $2.10 a share, from $960.3 million, or $4.64 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $2.53 from $2.40, to top the FactSet consensus of $2.48. Revenue increased 3.7% to $49.15 billion, below the FactSet consensus of $49.98 billion. Pharmaceutical distribution services revenue grew 3.4% to $47.1 billion, as specialty product sales, including COVID-19 treatments, increased, but missed expectations of $47.4 billion. Cost of goods sold rose 3.5% to $47.62 billion. For 2021, the company revised its adjusted EPS guidance range up to $8.45 to $8.60 from $8.40 to $8.60. The stock has rallied 28.7% year to date through Tuesday, while the S&P 500 gained 10.9%.
3:52 a.m. May 4, 2021 - By Jaimy Lee
Bausch reports a $610 million loss in the first quarter of the yearShares of Bausch Health Cos. Inc. were down 2.3% in premarket trading on Tuesday after the company said it faced continued pressure on sales from the COVID-19 pandemic into the first quarter of this year. Bausch had a loss of $610 million, or $1.71 per share, in the first quarter of 2021, compared with a loss of $152 million, or 43 cents per share, in the same quarter a year ago. Bausch did not provide adjusted earnings per share for the quarter. The company reported $2.02 billion in sales for the first quarter of the year, up from $2.01 billion in the like quarter a year ago. The FactSet consensus was $2.05 billion. Much of Bausch's business continues to be affected by the pandemic, it said, citing declining sales of irritable bowel syndrome drug Xifaxin and lower sales of eye-care products for the quarter. Bausch said it still plans to move forward with spinning off the Bausch + Lomb eye-care business, which had $881 million in sales for the quarter, up from $875 million in the first quarter of 2020. Bausch's other business focuses on pharmaceuticals; it had $1.14 billion in sales, compared with $1.13 billion in the same quarter a year ago. Bausch's stock has gained 51.0% since the start of the year, while the S&P 500 is up 11.6%.
3:01 a.m. May 4, 2021 - By Tomi Kilgore
Pfizer beats earnings expectations and lifts guidance, as COVID-19 revenue outlook increases 73%Shares of Pfizer Inc. jumped 1.6% toward a near five-month high in premarket trading Tuesday, after the drug giant beat earnings expectations and raised its full-year outlook, as revenue expectations for its COVID-19 vaccine jumped 73%. Net income rose to $4.88 billion, or 86 cents a share, from $3.36 billion, or 60 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share increased to 93 cents from 63 cents, and beat the FactSet consensus of 77 cents. Revenue grew 45% to $14.58 billion, above the FactSet consensus of $13.54 billion. Vaccine revenue tripled, to $4.89 billion from $1.61 billion, while oncology revenue rose 18% to $2.86 billion and internal medicine revenue grew 11% to $2.59 billion. For 2021, the company raised its guidance ranges for adjusted EPS to $3.55 to $3.65 from $3.10 to $3.20 and for revenue to $70.5 billion to $72.5 billion from $59.4 billion to $61.4 billion, as revenue expectations for the COVID-19 vaccine (BNT162b2) increased to $26 billion from $15 billion. The revenue projection for BNT162b2 includes guidance for 1.6 billion doses expected to be delivered this year. The stock, which is on track to open at the highest prices seen since mid-December, has gained 8.2% year to date through Monday, while the S&P 500 has advanced 11.6%.
2:43 a.m. May 4, 2021 - By Tomi Kilgore
CVS stock surges to multiyear high after profit and revenue beats, raised outlookShares of CVS Health Corp. rallied 3.6% toward a 2 1/2-year high in premarket trading Tuesday, after the drugstore chain and health care services company reported first-quarter profit and sales that rose above expectations, with growth in all segments, and raised its full-year outlook. Net income rose to $2.22 billion, or $1.68 a share, from $2.01 billion, or $1.53 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew to $2.04 from $1.91, beating the FactSet consensus of $1.73. Revenue increased 3.5% to $69.10 billion, above the FactSet consensus of $68.36 billion. Pharmacy services revenue rose 3.8% to $36.32 billion to beat the FactSet consensus of $35.41 billion, retail and long-term care revenue grew 2.3% to $23.27 billion to top expectations of $23.11 billion and health care benefits revenue increased 6.7% to $20.48 billion to beat expectations of $20.06 billion. For 2021, the company raised its guidance range for adjusted EPS to $7.56 to $7.68 from $7.39 to $7.55, and affirmed it cash flow outlook of $12.0 billion to $12.5 billion. The stock, on track to open at the highest price seen since November 2018, has climbed 13.8% year to date, while the S&P 500 has gained 11.6%.
12:05 p.m. May 2, 2021 - By Quentin Fottrell
Is my boyfriend of 13 years entitled to half my house? I bought it 12 years ago — and he never helped with the bills ‘He is now claiming that he’s entitled to half the value of the house’‘He is now claiming that he’s entitled to half the value of the house.’
4:45 a.m. April 30, 2021 - By Jaimy Lee
AbbVie's stock is up 2.0% as Humira sales top $4.8 billion in sales in the first quarterShares of AbbVie Inc. gained 2.0% in premarket trading on Friday after it beat earnings expectations and saw a noticeable jump in pharmaceutical revenue for the first quarter of 2021. The diagnostics company had earnings of $3.5 billion, or $1.99 earnings per share, in the first quarter of 2021, compared with $3.0 billion, or $2.02 earnings per share, in the same quarter a year ago. AbbVie's adjusted earnings per share for the quarter were $2.95, against a FactSet consensus of $2.81. The company generated $13.0 billion in revenue for the quarter in 2021, up from $8.6 billion in the same quarter in 2020. The FactSet consensus was $12.7 billion. Rheumatoid arthritis drug Humira remains AbbVie's top-selling drug with $4.8 billion in sales, up from $4.7 billion in the same quarter a year ago. Botox, the cosmetic filler, had sales of $477 million. AbbVie closed its acquisition of Allergan, which marketed Botox, in May of last year. The company raised its guidance for the year, with adjusted EPS projected to be $12.37 to $12.57 for 2021, from $12.32 to $12.52. AbbVie's stock is up 3.5% for the year, while the S&P 500 has gained 12.1%.
9:36 a.m. April 29, 2021 - By Tomi Kilgore
Teladoc stock tumbles after another quarter of wider-than-expected loss prompts multiple price target cutsShares of Teladoc Health Inc. tumbled 9.3% toward a near 11-month low in afternoon trading Thursday, after the provider of tele-healthcare services reported yet another quarterly loss that was wider than expected. The stock has now plunged 42.6%, since the stock shot up 140% in a year to a record $294.54 on Feb. 8 as the company was a seen as a beneficiary of the COVID-19-related stay-at-home measures. But late Wednesday, the company reported a net loss that widened to $199.6 million, or $1.31 a share, from $29.6 million, or 40 cents a share, missing the FactSet per-share loss consensus of 54 cents, marking the fifth-straight miss. The company has reported a quarterly loss for every quarter since it went public in July 2015. After Teladoc's report, no less than 14 of the 31 analysts surveyed by FactSet lower their price targets, to bring the average target down to $241.07 from $259.81 at the end of March. The stock, which is headed toward the lowest close since June 9, 2020, has now shed 15.4% year to date, while the SPDR Health Care Select Sector ETF has gained 6.9% and the S&P 500 has advanced 8.9%.
3:11 a.m. April 29, 2021 - By Tomi Kilgore
Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectationsShares of Bristol Myers Squibb Co. shed 2.1% in premarket trading Thursday, after the drug maker reported a first-quarter profit that came up short of expectations, as the COVID-19 pandemic reduced revenue growth by 5 percentage points. The company swung to net income of $2.02 billion, or 89 cents a share, from a loss of $775 million, or 34 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share increased to $1.74 from $1.72, but missed the FactSet consensus of $1.81. Revenue grew 3% to $11.07 billion, but was shy of the FactSet consensus of $1.13 billion. Among the company's top selling drugs, Revlimid sales rose 1% to $2.94 billion and Eliquis sales grew 9% to $2.89 billion. The company estimates that excluding COVID-19-related buying patterns from the prior year period, revenue would have grown 8%. For 2021, the company affirmed its adjusted EPS guidance range of $7.35 to $7.55. The stock has gained 6.5% year to date through Wednesday, while the S&P 500 has advanced 11.4%.
2:48 a.m. April 29, 2021 - By Tomi Kilgore
Merck stock drops after adjusted profit surprisingly falls, revenue comes up shortShares of Merck & Co. Inc. dropped 3.4% in premarket trading Thursday, after the drug giant reported first-quarter profit and revenue that missed expectations, as the COVID-19 pandemic and loss of market exclusivity weighed on pharmaceutical sales. Net income slipped to $3.18 billion, or $1.25 a share, from $3.22 billion, or $1.26 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share fell to $1.40 from $1.51, missing the FactSet consensus of a rise to $1.61. Revenue inched up to $12.08 billion from $12.06 billion, but was below the FactSet consensus of $12.61 billion, as pharmaceutical sales ticked up 0.2% to $10.68 billion. Among Merck's biggest drugs, Keytruda sales rose 19% to $3.90 billion but missed the FactSet consensus of $3.97 billion and Januvia/Janumet sales rose 1% to $1.30 billion but missed expectations of $1.34 billion. Animal health sales rose 17% to $1.4 billion. For 2021, Merck expects adjusted EPS of $6.48 to $6.68 and revenue of $51.8 billion to $53.8 billion, surrounding expectations of EPS for $6.49 and for revenue of $52.0 billion. The stock has dropped 5.8% year to date through Wednesday, while the Dow Jones Industrial Average has gained 10.5%.
3:40 a.m. April 28, 2021 - By Jaimy Lee
Teva's stock gains after it beats earnings expectationsShares of Teva Pharmaceutical Industries Ltd. gained 0.6% in premarket trading after the drug maker beat earnings expectations for the first quarter, even though sales of its multiple-sclerosis drug continue to dwindle. Teva had earnings of $77.0 million, or 7 cents per share, in the first quarter of 2021, compared to $66.0 million, or 6 cents per share, in the same quarter a year ago. Adjusted earnings per share were 63 cents, beating the FactSet consensus of 59 cents. Teva's revenue for the quarter was $3.9 billion, down from $4.3 billion in the first quarter of 2020. The FactSet consensus was $4.0 billion. The company attributed the decline in revenue to a number of factors, including a 5% drop in sales in North America and falling sales of Copaxone in North America, down 17% to $164 million, and in Europe, down 8% to $100 million. Copaxone was once the company's top-selling drug. Teva reaffirmed its guidance for 2021, saying it still expects revenue of $16.4 billion to $16.8 billion and EPS of $2.50 to $2.70. Teva's stock is up 10.4% for the year, while the S&P 500 has gained 11.4%.
3:32 a.m. April 28, 2021 - By Callum Keown
GlaxoSmithKline delivers profit beat, but sales disappointGlaxoSmithKline stock ticked higher on Wednesday after the British drugmaker beat profit expectations and said progress had been made on plans to split the company into two. GlaxoSmithKline reported turnover of £7.42 billion ($10.26 billion) in the first quarter, a 15% fall on the previous year at constant exchange rates, missing consensus estimates for £7.83 billion. Pre-tax profit fell 9% to £1.52 billion and operating profit declined 8% to £1.69 billion also lower than the Dow Jones consensus. However, adjusted earnings per share (EPS) of 22.9 pence beat the consensus for 21.9 pence. The company confirmed its full-year guidance for mid to high-single digit percentage adjusted EPS decline. Its 2022 outlook also remained unchanged, as the company saw meaningful improvements in revenues and margins. GlaxoSmithKline said it was "on track" to separate into two -- a new GSK and a standalone consumer healthcare company in 2022 -- and will reveal more details in June.
2:47 a.m. April 28, 2021 - By Ciara Linnane
Boston Scientific tops Q1 estimates and offers upbeat guidanceBoston Scientific Corp. shares rose 1.5% in premarket trade Wednesday, after the medical device company beat estimates for its first-quarter earnings and offered upbeat guidance. The company said it had net income of $327 million, or 23 cents a share, in the quarter, up from $11 million, or 1 cent a share, in the year-earlier period. Adjusted per-share earnings came to 37 cents, ahead of the 31-cent FactSet consensus. Sales rose to $2.752 billion from $2.543 billion a year ago, also ahead of the FactSet consensus of $2.616 billion. Sales at the company's endoscopy segment rose 12.9% to $499 million, while sales at the urology and pelvic health segment rose 8.7% to $361 million. In the company's medsurg business, sales rose 11.1% to $860 million, while sales at the rhythm and neuro segment rose 6.8% to $750 million. Sales at the company's cardiovascular segment rose 10% to $1.129 billion. The company is now expecting full-year sales to grow 16% to 19% and for adjusted EPS to range from $1.53 to $1.60 a share. For the second quarter, it expects sales to grow 46% to 50% and for adjusted EPS to range from 36 cents to 38 cents. The FactSet consensus is for second-quarter EPS of 35 cents and full-year EPS of $1.54. Shares have gained 18% in the year to date, while the SPDR S&P Biotech ETF has fallen 1% and the S&P 500 has gained 11.5%.
2:41 a.m. April 28, 2021 - By Tomi Kilgore
Humana beats profit and revenue expectations, affirms full-year outlookHumana Inc. reported Wednesday first-quarter profit and revenue that rose above expectations, boosted by strong individual Medicare Advantage and state-based contract membership growth. The health insurance services company's stock was still inactive in premarket trading. Net income rose to $1.04 billion, or $6.39 a share, from $717 million, or $3.56 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew to $7.67 from $5.40, and beat the FactSet consensus of $7.07. Revenue increased 9.2% to $20.67 billion, above the FactSet consensus of $20.49 billion. The company affirmed its 2021 guidance ranges for adjusted EPS of $21.25 to $21.75 and its individual Medicare Advantage membership growth of 425,000 to 475,000. The FactSet consensus for 2021 EPS is $21.54. The stock has gained 9.4% year to date, while the S&P 500 has advanced 11.5%.
10:31 a.m. April 27, 2021 - By Tomi Kilgore
3M stock drops despite earnings beat, as cost inflation seen taking a bigger bite out of profitsShares of 3M Co. sank 2.4% in afternoon trading, enough to pace the Dow Jones Industrial Average's decliners, even as the consumer, health care and industrial products company . The stock's $4.81 price decline was shaving about 32 points off the Dow's price, while the Dow was up 7 points, or less than 0.1%. Investors may be concerned about 3M's comments regarding the expected negative impact that will have on earnings this year. In the first quarter, Chief Financial Officer Monish Patolawala said 3M experienced increasing costs, particularly for raw materials and logistics, due primarily to the stronger demand, the ongoing COVID-19 pandemic and Winter Storm Uri. "In our view, we expect global supply chain dynamics to remain fluid and for raw material and logistics headwinds to persist," Patolawala said, according to a FactSet transcript of the post-earnings conference call with analysts. "Therefore, we now anticipate a full-year raw materials and logistics headwind of 30 cents-to-50 cents per share versus a prior expectation of flat to a 10-cent headwind at the start of the year."
3:28 a.m. April 27, 2021 - MarketWatch
Centene earnings buoyed by Medicare/MedicaidCentene Corp. Tuesday posted better-than-expected profit and revenue growth for the first quarter, as stronger results from its Medicaid and Medicare businesses offset declining revenue from commercial programs.
2:41 a.m. April 27, 2021 - By Tomi Kilgore
3M stock climbs after profit beats, and all 4 business segments top revenue forecastsShares of 3M Co. climbed 1.5% toward a two-year high in premarket trading Tuesday, after the consumer, health care and industrial products company, which makes Post-it Notes and N95 face masks, reported first-quarter profit and revenue that beat expectations, and affirmed its full-year outlook. Net income increased to $1.62 billion, or $2.77 a share, from $1.31 billion, or $2.27 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $2.77 was well above the FactSet consensus of $2.29 a share. Sales rose 9.6% to $8.85 billion, beating the FactSet consensus of $8.44 billion. Health care sales rose 6.8% to $2.2 billion, above the FactSet consensus of $2.17 billion; safety and industrial sales grew 13.7% to $3.3 billion, topping expectations of $3.19 billion; consumer sales increased 9.8% to $1.4 billion, above expectations of $1.34 billion; and transportation and electronics sales rose 13.1% to $2.5 billion, compared with expectations of $2.32 billion. "Our four industry-leading businesses are delivering strong results, while we accelerate 3M's digital transformation and sustainability efforts with significant new goals to improve air and water quality," said Chief Executive Mike Roman. For 2021, 3M affirmed its EPS guidance range $9.20 to $9.70 and its sales growth outlook of positive growth of 5% to 8%. The stock has climbed 7.0% over the past three months through Monday, while the Dow Jones Industrial Average has gained 12.1%.
2:40 a.m. April 27, 2021 - By Ciara Linnane
Eli Lilly shares slide 5% premarket as earnings fall short of estimates and guidance lags consensusEli Lilly & Co. shares slid 5% in premarket trade Tuesday, after the drug company posted weaker-than-expected first-quarter earnings and offered guidance that is below consensus. The company posted net income of $1.355 billion, or $1.49 a share, in the quarter, down 7% from $1.457 billion, or $1.60 a share, in the year-earlier period. Adjusted per-share earnings came to $1.87, below the $2.12 FactSet consensus. Revenue rose 16% to $6.806 billion from $5.859 billion, also below the FactSet consensus of $6.932 billion. Operating costs rose 11% to $3.261 billion, driven by about $220 million of R&D costs relating to COVID-19 antibody therapies. The company also recognized asset impairment, restructuring and other special charges of $211.6 million, stemming from the decision to sell the rights to Qbrexza, and integration costs relating to the acquisition of Prevail Therapeutics Inc. The company updated its full-year guidance, and now expects adjusted EPS to range from $7.80 to $8.00 and for revenue to range from $26.6 billion to $27.6 billion. The FactSet consensus is for EPS of $8.24 and revenue of $27.7 billion. Shares have gained 10.9% in the year to date, while the S&P 500 has gained 11.5%.
5:03 a.m. April 22, 2021 - By Tomi Kilgore
Privia Health sets IPO terms, that could value that company at up to $2 billionPrivia Health Group Inc. has set terms for its initial public offering, as the Virginia-based provider of services to optimize physician practices could be valued at up to $1.97 billion. The IPO is expected to price between $17 and $19 a share. The company is offering 2.8 million shares in the IPO, to raise up to $53.2 million, while selling shareholders are offering 16.7 million shares to raise up to $317.3 million. The stock is expected to list on the Nasdaq under the ticker symbol "PRVA." Goldman Sachs and J.P. Morgan are the lead underwriters. The company recorded net income of $31.2 million on revenue of $817.1 million in 2020, after net income of $8.2 million on revenue of $786.4 million in 2019. The company is looking to go public at a time of tempered investor demand for IPOs, as the Renaissance IPO ETF has dropped 11.5% over the past three months while the S&P 500 has gained 8.6%.
3:44 a.m. April 22, 2021 - By Tomi Kilgore
HCA Healthcare stock jumps into record territory after profit and revenue beats, raised outlookShares of HCA Healthcare Inc. hiked up 2.5% into record territory in premarket trading Thursday, after the hospital operator reported first-quarter profit that more than doubled and beat expectations, and raised its full-year outlook, even as same-facility admissions declined. Net income grew to $1.42 billion, or $4.14 a share, from $581 million, or $1.69 a share, in the year-ago period. The FactSet consensus for earnings per share was $3.32. Revenue increased 8.7% to $13.98 billion, beating the FactSet consensus of $13.63 billion. Same-facility equivalent admissions declined 6.5%, while same-facility revenue per equivalent admission increased 16.6%. Same-facility emergency room visits dropped 18.4% and same-facility inpatient surgeries were down 5.4%, while same-facility outpatient surgeries increased 2.3%. For 2021, the company raised its guidance ranges for EPS to $13.30 to $14.30 from $12.10 to $13.10 and for revenue to $54.0 billion to $55.5 billion from $53.5 billion to $55.5 billion. The stock, which closed at a record $197.53 on Wednesday, has rallied 18.3% over the past three months, while the S&P 500 has gained 8.6%.
2:14 a.m. April 21, 2021 - By Tomi Kilgore
Anthem's stock set to rise after profit beat and upbeat outlook, although revenue missedShares of Anthem Inc. were indicated up about 2% in premarke trading Wednesday, after the health benefits company reported first-quarter profit that beat expectations and provided an upbeat full-year outlook, but revenue that missed expectations as premiums rose less than forecast. TNet income rose to $1.67 billion, or $6.71 a share, from $1.52 billion, or $1.52 a share, in the year-ago period. Excluding nonrecurring items, such as net negative adjustments, adjusted earnings per share came to $7.01, above the FactSet consensus of $6.38. Total revenue grew 9.3% to $32.39 billion, below the FactSet consensus of $32.97 billion, as premiums increased 8.5% to $27.68 billion but missed expectations of $28.10 billion. For 2021, the company expects adjusted EPS "greater than" $25.10, compared with the FactSet consensus of $24.70. Medical enrollment rose 3.3% to a total of 43.5 million, reflecting growth in its Medicaid and Medicare businesses. The company said it expects the "positive momentum" in the first quarter to persist through the rest of the year. The stock has run up 18.9% year to date, while the S&P 500 has gained 10.1%.
1:59 p.m. April 20, 2021 - By Andrew Keshner
Floyd family attorney Ben Crump says Derek Chauvin’s murder conviction is ‘painfully earned justice’ — here’s what gave him hope months earlier A jury found the former Minneapolis officer guilty on all three counts TuesdayA jury found the former Minneapolis officer guilty on all three counts Tuesday.
7:21 a.m. April 20, 2021 - By Alicia H. Munnell
Has COVID-19 pushed more people into retirement? Yes, and particularly among the higher paid Yes, and particularly among the higher paid
4:02 a.m. April 20, 2021 - By Jaimy Lee
Abbott's stock drops 3%, though earnings more than tripled for the medical test company in the first quarterShares of Abbott Laboratories were down 3.2% in premarket trading on Tuesday after the company beat earnings expectations during a quarter in which sales of its COVID-19 tests made up 20% of total revenue. Abbott had earnings of $1.8 billion, or $1.00 per share, in the first quarter of 2021, compared with $544 million, or 30 cents, in the same quarter a year ago. Adjusted earnings per share were $1.32, against a FactSet consensus of $1.27. The company had sales of $10.4 billion for the quarter, up from $7.7 billion in the first quarter of 2020, against a FactSet consensus of $10.7 billion. This was driven in large part by $2.2 billion in sales of its COVID-19 tests, including $1.8 billion that came in from the company's rapid-testing platforms. Abbott said it anticipates adjusted EPS of $5.00 for 2021; the FactSet consensus is $5.06. Abbott's stock has gained 27.1% over the last year, while the broader S&P 500 is up 44.8%.
2:45 a.m. April 20, 2021 - By Tomi Kilgore
J&J beats profit and sales expectations, boosts dividend; COVID-19 vaccine adds $100 million to salesJohnson & Johnson reported Tuesday first-quarter profit and sales that rose above expectations, citing strength in its pharmaceutical business and continued recovery in medical devices. The drug giant's stock slipped 0.2% in premarket trading. Net income increased to $6.20 billion, or $2.32 a share, from $5.80 billion, or $2.17 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew 12.6% to $2.59, above the FactSet consensus of $2.34. Sales increased 7.9% to $22.32 billion, beating the FactSet consensus of $21.98 billion. Pharmaceutical sales rose 9.6% to $12.20 billion, to top the FactSet consensus of $12.11 billion, while medical devices sales increased 10.9% to $6.58 billion to beat expectations of $6.21 billion. COVID-19 vaccine sales were $100 million. For 2021, the company revised its adjusted EPS guidance range to $9.42 to $9.57 from $9.40 to $9.60. Separately, J&J said it raised its quarterly dividend by 5% to $1.01 a share, with the new dividend payable June 8 to shareholders of record on May 25. The stock has gained 3.4% year to date through Monday, while the Dow Jones Industrial Average has advanced 11.3%.
10:32 a.m. April 15, 2021 - By Tomi Kilgore
Agilon Health stock soars in its debut to lift the company's valuation above $11 billionInvestors cheered the public debut of Agilon Health Inc. , as shares of the California-based provider of support services for primary care physicians opened 23% above its initial public offering price, then extended gains. Agilon's IPO priced late Wednesday at $23.00 a share, at the top of the expected range of between $20 and $23 a share, to value the company at $8.85 billion. The company offered 46.6 million shares in the IPO to raise $1.07 billion. J.P. Morgan, Goldman Sachs and BofA Securities were the lead underwriters. The stock opened at $28.25 at 12:13 p.m. Eastern, and was recently trading 28.2% above the IPO price at $29.48, to push the valuation up to $11.34 billion. Agilon recorded a net loss of $60.1 million on revenue of $1.22 billion in 2020, after a loss of $282.6 million on revenue of $794.4 million in 2019. The company went public at a time that the Renaissance IPO ETF has slipped 3.4% over the past three months, while the SPDR Health Care Select Sector ETF has gained 3.2% and the S&P 500 has rallied 10.6%.
3:30 a.m. April 15, 2021 - By Tonya Garcia
Rite Aid reports narrower losses, sales beatRite Aid Corp. shares rose 1.3% in Thursday premarket trading after the pharmacy retailer reported a fourth-quarter sales beat. Net losses totaled $18.5 million, or 34 cents per share, after a loss of $324.7 million, or $6.08 per share, last year. Adjusted losses of 78 cents per share were ahead of the FactSet consensus for a loss of 90 cents per share. Revenue of $5.92 billion was up from $5.73 billion last year and also ahead of the FactSet consensus for $5.85 billion. The quarter was impacted by "a historically soft cough, cold and flu season, the deferral of elective procedures and related acute prescription volume and the impact of COVID-19 on selling, general and administrative expenses," Chief Executive Heyward Donigan said in a statement. For March and April to date, Rite Aid has administered two million COVID-19 vaccine shots, and Donigan said prescription trends heading back "to positive levels." For the first quarter, Rite Aid is guiding for net income between $10 million and a net loss of $10 million and retail pharmacy revenue between $6.1 billion and $6.3 billion. The company expects COVID-19 to continue to have an impact. The FactSet consensus is for pharmacy sales of $6.084 billion. Rite Aid stock is up 20.3% for the year to date while the S&P 500 index [s spx] has gained 9.8% for the period.
3:17 a.m. April 15, 2021 - By Tomi Kilgore
Thermo Fisher to buy PPD, in a cash deal valued at $17.4 billion, plus debtShares of PPD Inc. rallied 7.3% in premarket trading Thursday, after Thermo Fisher Scientific Inc. to buy the pharmaceutical-testing company in a cash deal valued at $17.4 billion, plus the assumption of $3.5 billion in debt. Thermo Fisher shares gained 3.1% ahead of the open. Under terms of the deal, Thermo Fisher will pay $47.50 for each PPD share outstanding, which is a 10.5% premium to Wednesday's closing price of $43.00, and implies a market capitalization for PPD of $16.64 billion. The deal was reported by late Wednesday. Thermo Fisher said it expects cost synergies of about $75 million after the deal's closing, which is expected to occur by the end of 2021, and expects the deal to add $1.40 to adjusted earnings per share in the first 12 months after the close. PPD's stock has rallied 25.7% year to date through Wednesday and Thermo Fisher shares have edged up 2.6%, while the S&P 500 has gained 9.8%.
2:11 a.m. April 15, 2021 - By Tomi Kilgore
UnitedHealth stock rises toward a record after profit and revenue beats, raised outlookShares of UnitedHealth Group Inc. jumped 1.7% into record territory in premarket trading Thursday, after the health care services company reported first-quarter profit and revenue that rose above expectations and raised its full-year outlook. "COVID-19 treatment and testing during the quarter was higher than expected, paired with higher elective care deferral patterns," the company said in a statement. Net income rose to $4.86 billion, or $5.08 a share, from $3.38 billion, or $3.52 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew to $5.31 from $3.72, beating the FactSet consensus of $4.39. Total revenue increased 9.0% to $70.20 billion, above the FactSet consensus of $69.02 billion, as premiums rose 9.6% to $55.49 billion to beat expectations of $54.57 billion. Revenue for the Optum business grew 10.8% to $36.4 billion. The company raised its 2021 adjusted EPS guidance range to $18.10 to $18.60 from $17.75 to $18.25. The stock, which is on track to open above the March 29 record close of $379.06, has advanced 7.1% year to date, while the Dow Jones Industrial Average has gained 9.8%.
9:50 a.m. April 3, 2021 - By Quentin Fottrell
My parents want to use $300,000 in retirement savings to pay off $160,000 left on their home. Is that a good idea? ‘I would like to be able to help them financially and be their safety net, but my means are limited’‘I would like to be able to help them financially and be their safety net, but my means are limited.’
3:26 a.m. March 31, 2021 - By Tonya Garcia
Walgreens sales miss expectations after weak cold and flu seasonWalgreens Boots Alliance Inc. reported fiscal second-quarter net income of $1.03 billion, or $1.19 per share, up from $946.0 million, or $1.07 per share last year. Adjusted EPS of $1.40 beat the FactSet consensus for $1.10 per share. Sales of $32.78 billion were up from $31.34 billion last year but below the FactSet consensus for $36.59 billion. Walgreens total excludes sales from discontinued operations of $4.8 billion. Comparable sales in the U.S. fell 3.5% due to a weak cough, cold and flu season. Comp sales for Boots UK fell 17.9% as COVID-19 restrictions reduced foot traffic on major high streets and transportation hubs. "Overall, we have achieved a good financial quarter with results well ahead of expectations, despite significant impacts from COVID-19, and we have raised our full-year EPS guidance," said Walgreens' new Chief Executive Roz Brewer in a statement. The former Starbucks Corp. executive assumed the role on . "I am optimistic about our ability to drive sustainable, long-term value for our shareholders, while acknowledging that there is still work to be done to stabilize the base business." Walgreens raised its fiscal 2021 adjusted EPS guidance to mid-to-high single digit growth in constant currency from low single-digit growth. The pharmacy retailer also expects the $6.5 billion divestiture of to be complete before the end of the fiscal year. Walgreens says it has administered eight million COVID-19 vaccinations and conducted five million COVID-19 tests. Walgreens stock rose 2.6% in Wednesday premarket trading and have gained 15.8% over the past year. The S&P 500 index is up 53.2% for the last 12 months.
3:13 a.m. March 25, 2021 - By Tomi Kilgore
Diversey to go public as IPO prices well below expected range, dropping valuation to $4.6 billionDiversey Holdings Ltd. is set to go public Thursday, after the hygiene and infection prevention products company's initial public offering priced well below the expected range. The company said late Wednesday that it sold 46.15 million shares at $15 a share to raise $692.3 million, compared with the expected pricing range of between $18 and $21 a share. The IPO pricing dropped the value of the company to $4.56 billion from $5.92 billion at the midpoint of the expected range. The stock is expected to trade on the Nasdaq under the ticker symbol "DSEY." Citigroup, Morgan Stanley and J.P. Morgan are the book-running managers. The company recorded a net loss of $38.5 million on revenue of $2.63 billion in 2020 after a loss of $109.0 million on revenue of $2.62 billion in 2019. The company is going public at a time of tempered investor demand for IPOs, as the Renaissance IPO ETF has dropped 12.3% over the past three months while the S&P 500 has gained 5.0%.
1:12 p.m. March 24, 2021 - By Andrew Keshner
Equal Pay Day: How paid-leave and child-care policies failed to close gender pay gap Women typically need at least one extra degree to earn as much as their male colleaguesWomen typically need at least one extra degree to earn as much as their male colleagues.
12:20 p.m. March 18, 2021 - By Jon Swartz
Hims & Hers stock dips 8% despite big hike in salesShares of Hims & Hers Health Inc. were down 8% in extended trading Thursday after the telehealth-consultation company announced fiscal fourth-quarter results. Hims & Hers reported a net loss of $5.2 million, compared with a net loss of $12.4 million in the year-ago quarter. The company's adjusted net loss was $3.1 million. Revenue surged 67% to $41.5 million from $24.8 million a year ago. Total revenue last year grew 80% to $148.8 million. Analysts surveyed by FactSet had expected a loss of 16 cents a share on revenue of $37 million. Hims & Hers' stock is up 69% over the last 12 months. The broader S&P 500 index has improved 62.5% this year.
Browse topics:

Filter results by

Industry

Financial Services (614)

Software (612)

Manufacturing (543)

Retail (542)

Health-care (413)

Internet (314)

Location

Us (3172)

Asia Pacific (316)

Europe (289)

China (236)

Eu (232)

Canada (60)

Link to MarketWatch's Slice.